title: Soluble complement receptor-1 protects heart, lung, and cardiac myofilament function from cardiopulmonary bypass damage.
abstract: BACKGROUND
  Host defense system activation occurs with cardiopulmonary bypass (CPB) and is thought to contribute to the pathophysiological consequences of CPB. Complement inhibition effects on the post-CPB syndrome were tested with soluble complement receptor-1 (sCR1).
  
  
  RESULTS
  Twenty neonatal pigs (weight 1.8 to 2.8 kg) were randomized to control and sCR1-treated groups. LV pressure and volume, left atrial pressure, pulmonary artery pressure and flow, and respiratory system compliance and resistance were measured. Preload recruitable stroke work, isovolumic diastolic relaxation time constant (tau), and pulmonary vascular resistance were determined. Pre-CPB measures were not statistically significantly different between the 2 groups. After CPB, preload recruitable stroke work was significantly higher in the sCR1 group (n=5, 46.8+/-3.2x10(3) vs n=6, 34.3+/-3.7x10(3) erg/cm(3), P=0.042); tau was significantly lower in the sCR1 group (26.4+/-1.5, 42.4+/-6. 6 ms, P=0.003); pulmonary vascular resistance was significantly lower in the sCR1 group (5860+/-1360 vs 12 170+/-1200 dyn. s/cm(5), P=0.009); arterial PO(2) in 100% FIO(2) was significantly higher in the sCR1 group (406+/-63 vs 148+/-33 mm Hg, P=0.01); lung compliance and airway resistance did not differ significantly. The post-CPB Hill coefficient of atrial myocardium was higher in the sCR1 group (2.88+/-0.29 vs 1.88+/-0.16, P=0.023).
  
  
  CONCLUSIONS
  sCR1 meaningfully moderates the post-CPB syndrome, supporting the hypothesis that complement activation contributes to this syndrome.
authors.affiliation: Department of Surgery, Duke University, Durham, NC, USA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Chai
authors.forename: R
authors.initials: R
authors.lastname: Nassar
authors.forename: A E
authors.initials: AE
authors.lastname: Oakeley
authors.forename: D M
authors.initials: DM
authors.lastname: Craig
authors.forename: G
authors.initials: G
authors.lastname: Quick
authors.forename: J
authors.initials: J
authors.lastname: Jaggers
authors.forename: S P
authors.initials: SP
authors.lastname: Sanders
authors.forename: R M
authors.initials: RM
authors.lastname: Ungerleider
authors.forename: P A
authors.initials: PA
authors.lastname: Anderson
mesh_terms: D008841:Actin Cytoskeleton / Q000737:chemistry / Q000187:drug effects / Q000502:physiology; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D006331:Heart Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006334:Heart Function Tests; D008171:Lung Diseases / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D010100:Oxygen / Q000378:metabolism; D011183:Postoperative Complications / Q000517:prevention & control*; D020011:Protective Agents / Q000627:therapeutic use*; D011487:Protein Conformation; D011951:Receptors, Complement / Q000627:therapeutic use*; D012129:Respiratory Function Tests; D013552:Swine; D013997:Time Factors
chemical_list: D020011:Protective Agents; D011951:Receptors, Complement; D010100:Oxygen; D002118:Calcium